One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

Table 3 Characteristics of seven patients developing genotypic mutations to entecavir

	Group A (entecavir)		Group B (entecavir maleate)
	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7
Age, yr	32	34	28	29	43	34	21
Sex	Male	Male	Male	Male	Male	Male	Male
Prior LAM exposure	Yes	Yes	No	No	Yes	Yes	No
Prior ADV exposure	Yes	Yes	No	No	Yes	No	No
Baseline
HBeAg status	Positive	Positive	Positive	Positive	Positive	Positive	Positive
HBV DNA, log10 IU/mL	6.69	7.99	8.06	5.32	7.77	7.47	7.81
LAM resistance	No	No	No	No	No	Yes	No
ADV resistance	Yes	Yes	No	No	Yes	No	No
At maximum viral suppression
wk	24	48	72	84	48	12	120
HBV DNA, log10 IU/mL	4.07	1.18	2.97	1.76	2.26	4.78	TND
At time of resistance confirmed
wk	144	144	144	144	144	144	144
HBV DNA, log10 IU/mL	6.91	6.04	4.41	1.73	6.73	4.96	1.79
Mutational pattern	rtL180M	rtL180M	rtL180M	rtL180M	rtL180M	rtL180M	rtL180M
	rtS202G	rtS202G	rtS202G	rtV173L	rtT184S	rtS202G	rtT184S
	rtM204V	rtM204V	rtM204V	rtM204V	rtM204V	rtM204V	rtM204V
				rtM250V
Addition of ADV	Yes	Yes	Yes	No	Yes	Yes	No
HBV DNA, log10 IU/mL
Week 168	5.14	5.08	3.18	1.84	3.43	4.86	TND
Week 192	4.2	2.77	3.1	Missing	2.89	4.28	Missing

ADV: Adefovir dipivoxil; ETV: Entecavir; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; LAM: Lamivudine; TND: Target not detected.